Stevanato Q3 Revenue Up 8%, but Nexa Syringe Slowdown to Weigh on 2027 Growth
STVN is trading near its 52-week low of $12.89 (9.8% above the low) on elevated volume (11× avg).
Summary
Q3 revenue rose 8% to €326.1 million and net income climbed 16% to €41.8 million, with the top line entirely organic. Management kept its 2026 revenue guidance at €1.26–€1.28 billion, so the near-term outlook is unchanged. The new item is 2027: lower Nexa syringe volumes from one customer will moderate growth that year, though the company expects to backfill most of the affected capacity. That single-customer concentration is the thing to watch — the backfill execution determines whether 2027 is a soft patch or a real demand problem.
At the time of this announcement, STVN was trading at $14.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $12.89 to $27.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.